...
首页> 外文期刊>Mycopathologia >Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen
【24h】

Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen

机译:由于Talomyces(Penicillium)Marneffei的塔罗敏性(青霉素):在发现病原体后60年后的主要真菌病的临床趋势的见解

获取原文
获取原文并翻译 | 示例
           

摘要

Talaromycosis (penicilliosis) is a major fungal disease endemic across a narrow band of tropical countries of South and Southeast Asia. The etiologic agent is a thermally dimorphic fungus Talaromyces (Penicillium) marneffei, which was first isolated from a bamboo rat in Vietnam in 1956, but no formal description was published. In 1959, Professor Gabriel Segretain formally described it as a novel species Talaromyces (Penicillium) marneffei, and the human pathogenic potential of the fungus in Mycopathologia. The first natural human case of talaromycosis (penicillosis) was reported in 1973 and involved an American minister with Hodgkin's disease who lived in Southeast Asia. Sixty years after the discovery of the pathogen, talaromycosis caused by T. marneffei is recognized as an important human disease with the potential to cause high mortality in the absence of proper diagnosis and prompt treatment. Talaromycosis remains a significant infectious complication in HIV/AIDS patients and in patients with other immune defects. The disease is being recognized with an increasing frequency well beyond the traditional endemic areas. The natural reservoirs of T. marneffei in wild rodents are well-defined, which links the ecology with the epidemiology of talaromycosis in endemic areas. There is an urgent unmet need for rapid and affordable point-of-care diagnostic tests. We also need more clinical studies to define the best therapeutic options for the management of talaromycosis patients.
机译:Talomycosis(青霉症)是南亚和东南亚热带国家狭窄的特有的主要真菌疾病。病因型剂是一种热亚氏菌塔罗马菌(Penicillium)Marneffei,其于1956年首先从越南的竹大鼠中分离出来,但没有公布正式的描述。 1959年,Gabriel Segretain教授正式将其描述为一种新颖的塔拉莫氏菌(Penicillium)Marneffei,以及肌动症患者的真菌的人致病潜力。 1973年举报了第一个自然人菌菌菌(小石症)的案例,并涉及美国部长与霍奇金病,曾在东南亚生活。在发现病原体后六十年,由T.Marneffei引起的塔罗敏性被认为是一个重要的人类疾病,可能在没有适当的诊断和及时治疗的情况下引起高死亡率。塔罗敏性仍然是艾滋病毒/艾滋病患者和其他免疫缺陷患者的显着传染性并发​​症。这种疾病正在被频率越来越远,超出传统的流行区域。野生啮齿动物的T.Marneffei的天然储层是明确定义的,这与生态与流行区域塔拉内菌病的流行病联系起来。紧急未满足快速和实惠的护理点诊断测试需求。我们还需要更多的临床研究来定义术治疗术术治疗患者的最佳治疗方案。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号